BioCentury | Jan 25, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

...series B round on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1)...
...Rod Wong will join Attune's board. Attune Pharmaceuticals, New York, N.Y. Business: Inflammation Mark Zipkin ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein (KLKB1)...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1)...
...RTW Investments, RA Capital Advisors, Boxer Capital and Tang Capital Partners. Mark Zipkin, Staff Writer ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein (KLKB1) Inflammation...
BioCentury | Jan 23, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

...B round Wednesday on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1)...
...Boxer Capital and Tang Capital Partners. RTW's Rod Wong will join Attune's board. Mark Zipkin ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein (KLKB1) hereditary...
BioCentury | Oct 26, 2018
Clinical News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

...plc (LSE:SHP; NASDAQ:SHPG) to prevent recurrent attacks of HAE. FDA approved the human mAb against plasma kallikrein (KLKB1)...
BioCentury | Oct 19, 2018
Company News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

...plc (LSE:SHP; NASDAQ:SHPG) to prevent recurrent attacks of HAE. FDA approved the human mAb against plasma kallikrein (KLKB1)...
BioCentury | Sep 21, 2018
Clinical News

FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

...lanadelumab-flyo, which FDA approved in August. Shire plc (LSE:SHP; NASDAQ:SHPG) markets the human mAb against plasma kallikrein (KLKB1)...
BioCentury | Sep 19, 2018
Company News

FDA wants extra trial for Pharming's Ruconest as HAE prophylactic

...lanadelumab-flyo, which FDA approved in August. Shire plc (LSE:SHP; NASDAQ:SHPG) markets the human mAb against plasma kallikrein (KLKB1)...
BioCentury | Aug 31, 2018
Clinical News

FDA approves Shire's Takhzyro, first mAb to prevent HAE

...Treatment from Dyax Deal Clears Phase III Hurdle" ). FDA approved the human mAb against plasma kallikrein (KLKB1)...
...plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Takhzyro lanadelumab-flyo Business: Inflammation Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire plc Plasma kallikrein (KLKB1)...
BioCentury | Aug 23, 2018
Company News

FDA approves Shire’s Takhzyro, first mAb to prevent HAE

...Treatment from Dyax Deal Clears Phase III Hurdle" ). FDA approved the human mAb against plasma kallikrein (KLKB1)...
...on NASDAQ. News of the approval came after market hours. Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire plc Plasma kallikrein (KLKB1)...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...Staff Writer BCX7353 Firazyr, icatibant (JE049) KVD818 BioCryst Pharmaceuticals Inc. KalVista Pharmaceuticals Inc. Pharvaris Shire plc Bradykinin B2 receptor (BDKRB2) (B2R) Complement 1 (C1) esterase Plasma kallikrein (KLKB1)...
Items per page:
1 - 10 of 21